These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25950242)

  • 1. Subjective response as a consideration in the pharmacogenetics of alcoholism treatment.
    Roche DJ; Ray LA
    Pharmacogenomics; 2015; 16(7):721-36. PubMed ID: 25950242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.
    Setiawan E; Pihl RO; Benkelfat C; Leyton M
    Pharmacogenomics; 2012 Jul; 13(10):1161-72. PubMed ID: 22909206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic treatments for drug addiction: alcohol and opiates.
    Haile CN; Kosten TA; Kosten TR
    Am J Drug Alcohol Abuse; 2008; 34(4):355-81. PubMed ID: 18584566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
    Ray LA; Hutchison KE
    Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic treatment of alcoholism.
    Anton RF; Schacht JP; Book SW
    Handb Clin Neurol; 2014; 125():527-42. PubMed ID: 25307594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic influences on response to alcohol and response to pharmacotherapies for alcoholism.
    Enoch MA
    Pharmacol Biochem Behav; 2014 Aug; 123():17-24. PubMed ID: 24220019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The μ-opioid receptor and treatment response to naltrexone.
    Thorsell A
    Alcohol Alcohol; 2013; 48(4):402-8. PubMed ID: 23543091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
    Oslin DW; Leong SH; Lynch KG; Berrettini W; O'Brien CP; Gordon AJ; Rukstalis M
    JAMA Psychiatry; 2015 May; 72(5):430-7. PubMed ID: 25760804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
    Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
    Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging.
    Mann K; Vollstädt-Klein S; Reinhard I; Leménager T; Fauth-Bühler M; Hermann D; Hoffmann S; Zimmermann US; Kiefer F; Heinz A; Smolka MN
    Alcohol Clin Exp Res; 2014 Nov; 38(11):2754-62. PubMed ID: 25421512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity.
    Cservenka A; Yardley MM; Ray LA
    Am J Addict; 2017 Aug; 26(5):516-525. PubMed ID: 28134463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic approaches to the treatment of alcohol addiction.
    Heilig M; Goldman D; Berrettini W; O'Brien CP
    Nat Rev Neurosci; 2011 Oct; 12(11):670-84. PubMed ID: 22011682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacogenetics of alcohol use disorder.
    Jones JD; Comer SD; Kranzler HR
    Alcohol Clin Exp Res; 2015 Mar; 39(3):391-402. PubMed ID: 25703505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence.
    Anton RF
    Pharmacogenomics; 2008 Jun; 9(6):655-8. PubMed ID: 18518841
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review.
    Ray LA; Barr CS; Blendy JA; Oslin D; Goldman D; Anton RF
    Alcohol Clin Exp Res; 2012 Mar; 36(3):385-94. PubMed ID: 21895723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
    Ooteman W; Naassila M; Koeter MW; Verheul R; Schippers GM; Houchi H; Daoust M; van den Brink W
    Addict Biol; 2009 Jul; 14(3):328-37. PubMed ID: 19523047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking.
    Krishnan-Sarin S; Krystal JH; Shi J; Pittman B; O'Malley SS
    Biol Psychiatry; 2007 Sep; 62(6):694-7. PubMed ID: 17336941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.
    Oslin DW; Berrettini WH; O'Brien CP
    Addict Biol; 2006 Sep; 11(3-4):397-403. PubMed ID: 16961767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of alcohol, nicotine and drug addiction treatments.
    Sturgess JE; George TP; Kennedy JL; Heinz A; Müller DJ
    Addict Biol; 2011 Jul; 16(3):357-76. PubMed ID: 21362114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subjective Response to Alcohol as a Research Domain Criterion.
    Ray LA; Bujarski S; Roche DJ
    Alcohol Clin Exp Res; 2016 Jan; 40(1):6-17. PubMed ID: 26727518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.